期刊
NATURE CLINICAL PRACTICE ONCOLOGY
卷 5, 期 4, 页码 186-187出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ncponc1077
关键词
bevacizumab; glioblastoma multiforme; irinotecan; survival; toxicity